VONVENDI
Biological
Takeda Pharmaceuticals U.S.A., Inc.
Total Payments
$31.3M
Transactions
1,700
Doctors
600
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $10.0M | 170 | 117 |
| 2023 | $4.1M | 327 | 208 |
| 2022 | $2.1M | 247 | 89 |
| 2021 | $4.1M | 263 | 54 |
| 2020 | $4.5M | 215 | 39 |
| 2019 | $3.9M | 291 | 123 |
| 2018 | $1.7M | 137 | 51 |
| 2017 | $928,165 | 50 | 29 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Royalty or License | $27.4M | 34 | 87.3% |
| Unspecified | $3.7M | 806 | 11.9% |
| Consulting Fee | $139,727 | 59 | 0.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $80,535 | 17 | 0.3% |
| Food and Beverage | $21,370 | 759 | 0.1% |
| Travel and Lodging | $3,761 | 20 | 0.0% |
| Education | $269.14 | 5 | 0.0% |
Payments by Type
General
$27.6M
894 transactions
Research
$3.7M
806 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| RECOMBINANT VWF TO MINIMIZE MENORRHAGIA IN WOMEN WITH VON WILLEBRAND DISEASE | Takeda Pharmaceuticals U.S.A., Inc. | $798,252 | 0 |
| A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE (VWD) | Takeda Pharmaceuticals U.S.A., Inc. | $495,201 | 1 |
| PROSPECTIVE, RANDOMIZED, CROSSOVER TRIAL COMPARING RECOMBINANT VON WILLEBRAND FACTOR RVWF COMBINED WITH TRANEXAMIC ACID TA VS. TRANEXAMIC ACID TA ALONE TO MINIMIZE MENORRHAGIA IN WOMEN WITH TYPE 1 VON WILLEBRAND DISEASE THE VWD MINIMIZE STUDY | Shire North American Group Inc | $374,255 | 0 |
| VWD COMPSEQ A COMPREHENSIVE APPROACH TO GENETIC ANALYSIS IN VON WILLEBRAND DISEASE | Shire North American Group Inc | $332,529 | 0 |
| A PHASE 3, PROSPECTIVE, MULTICENTER, UNCONTROLLED, OPEN-LABEL CLINICAL STUDY TO DETERMINE THE EFFICACY, SAFETY, AND TOLERABILITY OF RVWF WITH OR WITHOUT ADVATE IN THE TREATMENT AND CONTROL OF BLEEDING EPISODES, THE EFFICACY AND SAFETY OF RVWF IN ELECTIVE AND EMERGENCY SURGERIES, AND THE PHARMACOKINETICS (PK) OF RVWF IN CHILDREN DIAGNOSED WITH SEVERE VON WILLEBRAND DISEASE | Takeda Pharmaceuticals U.S.A., Inc. | $313,386 | 0 |
| PROSPECTIVE, RANDOMIZED, CROSSOVER TRIAL COMPARING RECOMBINANT VON WILLEBRAND FACTOR (RVWF) COMBINED WITH TRANEXAMIC ACID (TA) VS. TRANEXAMIC ACID (TA) ALONE TO MINIMIZE MENORRHAGIA IN WOMEN WITH TYPE 1 VON WILLEBRAND DISEASE: THE VWD MINIMIZE STUDY | Takeda Pharmaceuticals U.S.A., Inc. | $216,374 | 0 |
| A PHASE 3, PROSPECTIVE, MULTICENTER, UNCONTROLLED, OPEN-LABEL CLINICAL STUDY TO DETERMINE THE EFFICACY, SAFETY, AND TOLERABILITY OF RVWF WITH OR WITHOUT ADVATE IN THE TREATMENT AND CONTROL OF BLEEDING EPISODES, THE EFFICACY AND SAFETY OF RVWF IN ELECTIVE AND EMERGENCY SURGERIES, AND THE PHARMACOKINETICS PK OF RVWF IN CHILDREN DIAGNOSED WITH SEVERE VON WILLEBRAND DISEASE | Shire North American Group Inc | $214,453 | 1 |
| A REAL-WORLD SAFETY AND EFFICACY STUDY OF FACTOR REPLACEMENT FOR CLINICAL SEVERE VON WILLBRAND DISEASE VND | Shire North American Group Inc | $127,942 | 0 |
| ATHN9: Severe VWD Study | Takeda Pharmaceuticals U.S.A., Inc. | $127,942 | 0 |
| TAK-577-5003: EVALUATION OF REAL-WORLD TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH VON WILLEBRAND DISEASE TREATED PROPHYLACTICALLY WITH VONVENDI ACROSS TREATMENT CENTERS IN THE US PO: 8000408251 | Takeda Pharmaceuticals U.S.A., Inc. | $97,309 | 0 |
| IISR-2020-103215 Randomized Trial Comparing Recombinant von Willebrand Factor (rVWF) Plus Tranexamic Acid (TA) vs. rVWF Alone to Reduce Postpartum Hemorrhage in Women with von Willebrand Disease: The VWD-Woman Trial | Takeda Pharmaceuticals U.S.A., Inc. | $94,909 | 0 |
| A PROSPECTIVE, PHASE 3, OPEN LABEL, INTERNATIONAL MULTICENTER STUDY ON EFFICACY AND SAFETY OF PROPHYLAXIS WITH RVWF IN SEVERE VON WILLEBRAND DISEASE | Shire North American Group Inc | $68,816 | 2 |
| A REAL-WORLD SAFETY AND EFFICACY STUDY OF FACTOR REPLACEMENT FOR CLINICAL SEVERE VON WILLBRAND DISEASE (VND) | Takeda Pharmaceuticals U.S.A., Inc. | $63,971 | 0 |
| A PHASE 3B, PROSPECTIVE, OPEN-LABEL, UNCONTROLLED, MULTICENTER STUDY ON LONG-TERM SAFETY AND EFFICACY OF RVWF IN PEDIATRIC AND ADULT SUBJECTS WITH SEVERE VON WILLEBRAND DISEASE VWD | Shire North American Group Inc | $47,551 | 1 |
| GEO: Evaluation of Real-World Treatment Patterns and Outcomes in Patients with Von Willebrand Disease Treated | Takeda Pharmaceuticals U.S.A., Inc. | $46,997 | 0 |
| REGULATION OF ADAMTS13 ACTIVITY BY PAD4 ENZYME RELEASED DURING NEUTROPHIL EXTRACELLULAR TRAP NET FORMATION | Shire North American Group Inc | $41,768 | 0 |
| EVALUATING THE EFFICACY OF RECOMBINANT ADAMTS13 BAX 930 ON MESENTERIC AND CEREBRAL THROMBOSIS IN VIVO IN MOUSE MODELS OF THROMBOTIC THROMBOCYTOPENIC PURPURA | Shire North American Group Inc | $41,497 | 0 |
| A PROSPECTIVE, PHASE 3, OPEN LABEL, INTERNATIONAL MULTICENTER STUDY ON EFFICACY AND SAFETY OF PROPHYLAXIS WITH RVWF IN SEVERE VON WILLEBRAND DISEASE | Takeda Pharmaceuticals U.S.A., Inc. | $37,544 | 2 |
| A Phase 3, Prospective, Multicenter, Uncontrolled, Open-Label Clinical Study to Determine the Efficacy, Safety, and Tolerability of rVWF With or Without ADVATE in the Treatment and Control of Bleeding Episodes, the Efficacy and Safety of rVWF in Elective and Emergency Surgeries, and the Pharmacokinetics PK of rVWF in Children Diagnosed With Severe Von Willebrand Disease | Shire North American Group Inc | $32,392 | 0 |
| TAK-577 - VONVENDI | Takeda Pharmaceuticals U.S.A., Inc. | $31,194 | 0 |
Top Doctors Receiving Payments for VONVENDI
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Boston, MA | $31.1M | 818 |
| , M.D | Pediatrics | Peoria, IL | $29,413 | 24 |
| , MD, MPH | Hematology | Boston, MA | $24,481 | 5 |
| , MD | Pediatric Hematology-Oncology | Nashville, TN | $13,854 | 8 |
| , M.D | Hematology | Los Angeles, CA | $13,241 | 11 |
| , M.D | Pediatrics | Houston, TX | $12,975 | 6 |
| , MD | Pediatric Hematology-Oncology | Beaufort, SC | $12,436 | 15 |
| Maissaa Janbain | Specialist | New Orleans, LA | $12,167 | 5 |
| , M.D | Pediatric Hematology-Oncology | Chicago, IL | $10,365 | 4 |
| , MD | Internal Medicine | Minneapolis, MN | $10,200 | 7 |
| , MD | Pediatric Hematology-Oncology | Milwaukee, WI | $8,725 | 2 |
| , M.D. M.P.H | Obstetrics & Gynecology | Washington, DC | $8,324 | 11 |
| , MD | Hematology | New York, NY | $6,328 | 3 |
| , MD, PHD | Hematology | Seattle, WA | $6,300 | 3 |
| , M.D | Pediatric Hematology-Oncology | Ann Arbor, MI | $6,008 | 2 |
| , MD | Specialist | Pittsburgh, PA | $5,500 | 2 |
| , MD | Hematology & Oncology | Seattle, WA | $3,605 | 2 |
| , MD | Pediatric Hematology-Oncology | Ann Arbor, MI | $3,600 | 1 |
| , MD | Hematology & Oncology | Milwaukee, WI | $3,241 | 3 |
| , M.D | Pediatric Hematology-Oncology | Lansing, MI | $3,055 | 3 |
| , MD | Blood Banking & Transfusion Medicine | Brooklyn, NY | $2,912 | 9 |
| , M.D | Pediatric Hematology-Oncology | Orange, CA | $2,250 | 1 |
| , MD | Pediatric Hematology-Oncology | New Orleans, LA | $2,058 | 4 |
| , M.D | Hematology | Pittsburgh, PA | $1,474 | 2 |
| , NP | Pediatric Hematology-Oncology | Washington, DC | $1,200 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Biological
- Total Payments $31.3M
- Total Doctors 600
- Transactions 1,700
About VONVENDI
VONVENDI is a biological associated with $31.3M in payments to 600 healthcare providers, recorded across 1,700 transactions in the CMS Open Payments database. The primary manufacturer is Takeda Pharmaceuticals U.S.A., Inc..
Payment data is available from 2017 to 2024. In 2024, $10.0M was paid across 170 transactions to 117 doctors.
The most common payment nature for VONVENDI is "Royalty or License" ($27.4M, 87.3% of total).
VONVENDI is associated with 20 research studies, including "RECOMBINANT VWF TO MINIMIZE MENORRHAGIA IN WOMEN WITH VON WILLEBRAND DISEASE" ($798,252).